Aktis Oncology, Inc. (AKTS) vs Teladoc Health, Inc. (TDOC)
A side-by-side comparison of Aktis Oncology, Inc. and Teladoc Health, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.64HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
TDOC
Teladoc Health, Inc.
$5.81HealthcareDelayed quote: Oct 6, 2026, 9:30 AM EDT
Total return — AKTS vs TDOC
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)TDOC -23.5% (-23.5%/yr)AKTS compounded faster over this window
AKTS TDOC
AKTS vs TDOC: by the numbers
- •TDOC is the larger company ($1.06B vs $995M market cap).
- •Both run net losses; TDOC's is the smaller (-7.13% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | TDOC |
|---|---|---|
| P/S ratio | 98.95 | 0.42 |
| P/B ratio | 2.05 | 0.81 |
| EV / EBITDA | N/A | 12.97 |
| FCF yield | N/A | 21.28% |
Profitability
| Metric | AKTS | TDOC |
|---|---|---|
| Gross margin | 100.00% | 73.53% |
| Operating margin | -1149.52% | -6.98% |
| Net margin | -727.04% | -7.13% |
| ROE | -15.09% | -13.54% |
| ROIC | -16.54% | -7.32% |
Growth (annualized)
| Metric | AKTS | TDOC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.85% |
| Total return CAGR (5Y) | N/A | -45.85% |
Go deeper
Dig into the metrics
Aktis Oncology ROETeladoc Health ROEAktis Oncology operating marginTeladoc Health operating marginAktis Oncology revenue growthTeladoc Health revenue growthAktis Oncology free cash flowTeladoc Health free cash flow
Aktis Oncology & Teladoc Health appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.